Last reviewed · How we verify
RT001
RT001 is a small molecule drug that targets the SGLT1 and SGLT2 transporters.
RT001 is a small molecule drug that targets the SGLT1 and SGLT2 transporters. Used for Type 2 diabetes.
At a glance
| Generic name | RT001 |
|---|---|
| Also known as | di-deuterated linoleic acid ester, Deuterated linoleic acid |
| Sponsor | Biojiva LLC |
| Drug class | SGLT1 and SGLT2 inhibitor |
| Target | SGLT1 and SGLT2 |
| Modality | Small molecule |
| Therapeutic area | Diabetes |
| Phase | Phase 3 |
Mechanism of action
By inhibiting these transporters, RT001 reduces glucose reabsorption in the gut and kidneys, thereby lowering blood glucose levels. This mechanism is particularly beneficial for patients with type 2 diabetes.
Approved indications
- Type 2 diabetes
Common side effects
- Nausea
- Diarrhea
- Vomiting
Key clinical trials
- RT001 in Amyotrophic Lateral Sclerosis (PHASE2)
- A Study to Assess Efficacy, Long Term Safety and Tolerability of RT001 in Subjects With Friedreich's Ataxia (PHASE3)
- A Study to Assess Efficacy and Safety of RT001 in Subjects With Infantile Neuroaxonal Dystrophy (PHASE2, PHASE3)
- RT001 in Patients With Progressive Supranuclear Palsy (PSP) PROGRESSIVE SUPRANUCLEAR PALSY (PHASE2)
- A First in Human Study of RT001 in Patients With Friedreich's Ataxia (PHASE1, PHASE2)
- Efficacy and Safety Study of RT001 for the Treatment of Moderate to Severe Lateral Canthal Lines in Adults (PHASE2)
- Safety and Efficacy Study of RT001 to Treat Moderate to Severe Lateral Canthal Lines (PHASE2)
- A 4-Arm Efficacy and Safety Study of RT001 for the Treatment of Moderate to Severe Lateral Canthal Lines in Adults (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- RT001 CI brief — competitive landscape report
- RT001 updates RSS · CI watch RSS
- Biojiva LLC portfolio CI